Platelet diagnostic imaging agents
AssigneeCellphire, Inc.
InventorsDaniel Allen SHEIK, Keith Andrew MOSKOWITZ
Life of this patent
Estimating the term…
Abstract
Provided herein are MRI agent-loaded platelets, methods of preparing MRI agent-loaded platelets, and methods of using MRI agent-loaded platelets. In some embodiments, methods of loading MRI agents into platelets include contacting platelets with an MRI agent, a cell penetrating peptide, and a loading buffer that can include a salt, a base, a loading agent, and optionally at least one organic solvent.
Claims22
A method of preparing MRI agent-loaded platelets, comprising:
- contacting platelets with an MRI agent coupled to a cell penetrating peptide;
- and a loading buffer comprising a salt, a base, a loading agent, and optionally at least one organic solvent,
- to form the MRI agent-loaded platelets.
A method of preparing MRI agent-loaded platelets, comprising:
- a) providing platelets;
- and
- b) contacting the platelets with an MRI agent coupled to a cell penetrating peptide;
- and a loading buffer comprising a salt, a base, a loading agent, and optionally at least one organic solvent
- to form the MRI agent-loaded platelets.
The method of any one of the preceding claims, wherein the platelets are treated with the MRI agent coupled to a cell penetrating peptide and with the loading buffer sequentially, in either order, or concurrently.
The method of any one of the preceding claims, wherein the platelets are pooled from a plurality of donors.
A method of preparing MRI agent-loaded platelets comprising
- A) pooling platelets from a plurality of donors;
- and
- B) contacting the platelets from step (A) with an MRI agent coupled to a cell penetrating peptide;
- and with a loading buffer comprising a salt, a base, a loading agent, and optionally at least one organic solvent, to form the MRI agent-loaded platelets.
The method of any one of the preceding claims, wherein the loading buffer comprises optionally at least one organic solvent.
The method of any one of the preceding claims, wherein the loading agent is a monosaccharide or a disaccharide.
The method of any one of the preceding claims, wherein the loading agent is sucrose, maltose, dextrose, trehalose, glucose, mannose, or xylose.
The method of any one of the preceding claims, wherein the platelets are isolated prior to a contacting step.
The method of any one of the preceding claims, wherein the platelets are selected from the group consisting of fresh platelets, stored platelet, and any combination thereof.
The method of any one of the preceding claims, wherein the MRI agent comprises Gadolinium or a nanoparticle.
The method of any one of the preceding claims, wherein the cell penetrating peptide is Tat, or a portion thereof.
The method of any one of the preceding claims, wherein the platelets are loaded with the MRI agent in a period of time of 1 minute to 48 hours.
The method of any one of the preceding claims, wherein the one or more organic solvents selected from the group consisting of ethanol, acetic acid, acetone, acetonitrile, dimethylformamide, dimethyl sulfoxide, dioxane, methanol, n-propanol, isopropanol, tetrahydrofuran (THF), N-methyl pyrrolidone, dimethylacetamide (DMAC), or combinations thereof.
The method of any one of the preceding claims, further comprising cold storing, cryopreserving, freeze-drying, thawing, rehydrating, and combinations thereof the MRI agent-loaded platelets.
MRI agent-loaded platelets prepared by the method of any one of the preceding claims.
The method of any one of the preceding claims, wherein the method does not comprise contacting the platelets with an organic solvent.
The method of any one of the preceding claims, wherein the method comprises optionally contacting the platelets with Prostaglandin E1.
The method of any one of the preceding claims, wherein the method comprises optionally contacting the platelets with a glycoprotein IIb/IIIa inhibitor.
Dependencies are inferred from the claim text.